Neurocrine Bioscienc (NBIX)

Jan 13, 2025, 7:04 PM EST - 4 days ago

Nxera Pharma Provides Update on Neurocrine's Progress with its Partnered Muscarinic Agonist Portfolio

Jan 8, 2025, 8:30 AM EST - 9 days ago

Neurocrine Biosciences Announces Publication on Traditional Glucocorticoid Treatment in Classic Congenital Adrenal Hyperplasia in Expert Review of Endocrinology & Metabolism

Jan 6, 2025, 4:01 PM EST - 11 days ago

Neurocrine Biosciences to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Dec 20, 2024, 8:00 AM EST - 4 weeks ago

Neurocrine Biosciences Announces Commercial Availability of CRENESSITY™ (crinecerfont) for Children and Adults With Classic Congenital Adrenal Hyperplasia

Dec 18, 2024, 10:11 AM EST - 4 weeks ago

Neurocrine Biosciences' Crenessity Approval Sets Stage For Diversified Revenue And Growth

Dec 13, 2024, 6:55 PM EST - 5 weeks ago

Neurocrine Biosciences Announces FDA Approval of CRENESSITY™ (crinecerfont), a First-in-Class Treatment for Children and Adults With Classic Congenital Adrenal Hyperplasia

Dec 13, 2024, 5:50 PM EST - 5 weeks ago

US FDA approves Neurocrine Biosciences' genetic disorder drug

Nov 26, 2024, 4:01 PM EST - 7 weeks ago

Neurocrine Biosciences to Participate at Investor Conferences in December

Nov 8, 2024, 11:02 AM EST - 2 months ago

Why Neurocrine Biosciences Stock Is Very Attractive At Current Levels

Nov 7, 2024, 8:30 AM EST - 2 months ago

Neurocrine Biosciences Presents New KINECT®-HD Data Showing Consistent Efficacy Across 19 Subgroups and Improvements in Aspects of Emotional Health With INGREZZA® (valbenazine) Capsules

Nov 5, 2024, 4:01 PM EST - 2 months ago

Neurocrine Biosciences to Participate at Investor Conferences in November

Nov 4, 2024, 8:30 AM EST - 2 months ago

Neurocrine Biosciences Presents Breadth of Data Demonstrating Holistic Improvements Over Time in Patients With Tardive Dyskinesia Following Treatment With INGREZZA® (valbenazine) Capsules

Nov 4, 2024, 8:25 AM EST - 2 months ago

Neurocrine Biosciences Presents New Data on INGREZZA® (valbenazine) Capsules at Psych Congress 2024: Majority of Long-Term Study Participants Achieved Remission of Tardive Dyskinesia

Oct 30, 2024, 3:11 PM EDT - 2 months ago

Neurocrine Biosciences, Inc. (NBIX) Q3 2024 Earnings Call Transcript

Oct 30, 2024, 7:00 AM EDT - 2 months ago

Neurocrine Biosciences Reports Third Quarter 2024 Financial Results and Raises 2024 INGREZZA Sales Guidance

Oct 10, 2024, 7:42 AM EDT - 3 months ago

Neurocrine: A Buy Amid CNS Pipeline Growth And Ingrezza's Strength (Rating Upgrade)

Oct 9, 2024, 4:01 PM EDT - 3 months ago

Neurocrine Biosciences Announces Conference Call and Webcast of Third Quarter 2024 Financial Results

Sep 30, 2024, 8:30 AM EDT - 3 months ago

Neurocrine Biosciences Presents Interim Data Demonstrating Robust and Sustained Improvements in Chorea Associated With Huntington's Disease Through Week 104 Irrespective of Antipsychotic Use

Sep 19, 2024, 4:01 PM EDT - 4 months ago

Neurocrine Biosciences to Participate at the TD Cowen 4th Annual Novel Mechanisms in Neuropsychiatry Virtual Summit

Sep 12, 2024, 4:31 PM EDT - 4 months ago

Neurocrine's experimental drug misses primary goal in schizophrenia trial

Sep 12, 2024, 4:05 PM EDT - 4 months ago

Neurocrine Biosciences Provides Update on ERUDITE™ Phase 2 Data for Luvadaxistat in Adults with Cognitive Impairment Associated with Schizophrenia

Sep 10, 2024, 4:01 PM EDT - 4 months ago

Neurocrine Biosciences to Participate at the 2024 Cantor Global Healthcare Conference

Sep 1, 2024, 7:30 PM EDT - 4 months ago

Nxera Pharma to Receive US$35 Million from Neurocrine Biosciences upon Positive Phase 2 Data for Partnered Schizophrenia Candidate NBI-1117568

Aug 29, 2024, 1:22 PM EDT - 5 months ago

Neurocrine Biosciences' Lower Dose Data Puts Its Schizophrenia Candidate In The Game, Analyst Upgrades Stock

Aug 28, 2024, 5:22 PM EDT - 5 months ago

Neurocrine: Buying Opportunity After Stock Price Drop On Schizophrenia Data

Aug 28, 2024, 4:05 PM EDT - 5 months ago

Neurocrine Biosciences to Participate at Investor Conferences in September

Aug 28, 2024, 1:11 PM EDT - 5 months ago

Neurocrine Biosciences: Disappointing Data From A Key Readout Hits The Stock Hard

Aug 28, 2024, 11:16 AM EDT - 5 months ago

As Regulators Gear Up To Decide On Bristol Myers' Schizophrenia Treatment, Neurocrine Biosciences' Data Disappoints Investors

BMY

Aug 28, 2024, 7:07 AM EDT - 5 months ago

Nxera Pharma Notes Positive Phase 2 Data for Partnered Schizophrenia Candidate NBI-1117568

Aug 28, 2024, 7:06 AM EDT - 5 months ago

Neurocrine's schizophrenia drug meets main goal in mid-stage study

Aug 28, 2024, 7:00 AM EDT - 5 months ago

Neurocrine Biosciences Reports Positive Phase 2 Data for NBI-1117568 in Adults with Schizophrenia

Aug 7, 2024, 4:01 PM EDT - 5 months ago

Neurocrine Biosciences to Present at the Canaccord Genuity 44th Annual Growth Conference

Aug 2, 2024, 10:49 AM EDT - 6 months ago

Neurocrine Biosciences Delivering Strong Core Results, And Significant Pipeline Value Could Be On The Way

Aug 1, 2024, 3:24 PM EDT - 6 months ago

Neurocrine Biosciences, Inc. (NBIX) Q2 2024 Earnings Call Transcript

Aug 1, 2024, 7:00 AM EDT - 6 months ago

Neurocrine Biosciences Reports Second Quarter 2024 Financial Results and Raises 2024 INGREZZA Sales Guidance

Jul 19, 2024, 10:35 AM EDT - 6 months ago

Neurocrine's Growing Sales, Profits Attracting Big Money

Jul 18, 2024, 8:30 AM EDT - 6 months ago

Neurocrine Biosciences Launches INGREZZA® SPRINKLE (valbenazine) Capsules to Ease Administration for Patients Experiencing Dysphagia or Difficulty Swallowing

Jul 11, 2024, 4:01 PM EDT - 6 months ago

Neurocrine Biosciences Announces Conference Call and Webcast of Second Quarter 2024 Financial Results

Jul 11, 2024, 9:56 AM EDT - 6 months ago

Neurocrine Biosciences: Diverse Pipeline, High Margins, And Growth Potential In Biotech

Jul 9, 2024, 10:32 AM EDT - 6 months ago

Neurocrine's Pipeline, Including Crinecerfont's Priority Review, Drives Long-Term Growth

Jul 1, 2024, 7:30 AM EDT - 7 months ago

Neurocrine Biosciences Announces U.S. FDA Accepts New Drug Applications and Grants Priority Review for Crinecerfont for Pediatric and Adult Patients with CAH

Jun 3, 2024, 8:01 AM EDT - 8 months ago

Neurocrine Biosciences Presented CAHtalyst™ Phase 3 Pediatric and Adult Studies, CAHtalog™ Registry and Disease- and Glucocorticoid-Related Comorbidities Data in CAH at ENDO 2024

Jun 3, 2024, 7:35 AM EDT - 8 months ago

Neurocrine Biosciences Announces Publication of Primary CAHtalyst™ Pediatric Phase 3 Study Results of Crinecerfont for the Treatment of CAH in The New England Journal of Medicine

Jun 3, 2024, 7:30 AM EDT - 8 months ago

Neurocrine Biosciences Announces Publication of Primary CAHtalyst™ Adult Phase 3 Study Results of Crinecerfont for the Treatment of CAH in The New England Journal of Medicine

May 29, 2024, 4:01 PM EDT - 8 months ago

Neurocrine Biosciences to Participate at Investor Conferences in June

May 28, 2024, 5:07 PM EDT - 8 months ago

Neurocrine founder-CEO Gorman to retire in October

May 28, 2024, 4:14 PM EDT - 8 months ago

Neurocrine Biosciences Announces CEO Succession Plan

May 28, 2024, 8:30 AM EDT - 8 months ago

Neurocrine Biosciences to Present New Phase 3 CAHtalyst™ Data in Adult and Pediatric Patients with CAH and Study Data for Modified-Release Hydrocortisone in Primary Adrenal Insufficiency and CAH at ENDO 2024

May 21, 2024, 4:05 PM EDT - 8 months ago

Neurocrine Biosciences Announces Publication of Phase 3 KINECT®-4 Post Hoc Analysis Demonstrating Clinically Meaningful and Sustained Improvement in Tardive Dyskinesia With Long-Term Use of INGREZZA® (valbenazine) Capsules

May 14, 2024, 8:30 AM EDT - 8 months ago

Neurocrine Biosciences Presented Baseline Data from the CAHtalyst™ Program in CAH and Study Data for Modified-Release Hydrocortisone in Primary Adrenal Insufficiency and CAH at ECE 2024